AIM
AIM
AMEX · Biotechnology

Aim Immunotech Inc

$0.16
+0.00 (+1.91%)
As of Nov 7, 2:53 AM ET ·
Financial Highlights (FY 2026)
Revenue
2.20M
Net Income
-348,468,255
Gross Margin
-45.4%
Profit Margin
-15,861.4%
Rev Growth
-14.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -45.4% -45.4% 50.8% 50.8%
Operating Margin -13,254.5% -11,929.1% -19.6% -21.6%
Profit Margin -15,861.4% -15,068.3% -22.2% -17.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.20M 2.57M 1.31M 1.61M
Gross Profit -999,119 -1,169,107 667.2K 816.8K
Operating Income -291,372,386 -306,851,330 -257,805 -347,025
Net Income -348,468,255 -366,980,376 -292,011 -275,194
Gross Margin -45.4% -45.4% 50.8% 50.8%
Operating Margin -13,254.5% -11,929.1% -19.6% -21.6%
Profit Margin -15,861.4% -15,068.3% -22.2% -17.1%
Rev Growth -14.5% -14.5% +20.5% -9.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.16M 1.06M
Total Equity — — 1.39M 1.56M
D/E Ratio — — 0.83 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -290,274,372 -322,678,040 -341,169 -390,753
Free Cash Flow — — -173,511 -203,411